Abstract

Rheumatoid arthritis (RA) is the most common connective tissue disease of autoimmune origin. The disease is characterized by chronic inflammation leading to bone erosions and organ involvement. RA is a progressive disease. It affects the quality of life, leading to disability and death mainly due to premature cardiovascular disease. Early diagnosis and appropriate treatment are essential for prognosis and quality of life improvement.In 2010 the American College of Rheumatology (ACR) and The European League Against Rheumatism (EULAR) established new RA classification criteria. Besides clinical symptoms it includes two immunologic criteria: rheumatoid factor (RF) and anti-citrullinated protein antibodies (anti-CCP antibodies). RF is the first well-known RA immunologic marker. It is observed in 80-85% of patients with RA. Elevated serum level of RF has been associated with increased disease activity, radiographic progression, and the presence of extraarticular manifestations. The sensitivity of RF is 50-90%, and specificity is 50-95%. Anti-CCP antibodies appear to be a more specific marker than RF. They are often present at the very beginning of the disease, or even years before the first symptoms. The prognostic value of anti-CCP antibodies is well established. High serum level of anti-CCP correlates with poor prognosis and early erosions of the joints. The sensitivity of anti-CCP2 is 48-80%, and specificity is 96-98%.New immunologic markers include anti-carbamylated protein antibodies (anti-CarP) and antibodies against heterogeneous nuclear ribonucleoproteins (anti-hnRNP A2/B1, RA33). Scientists aim to identify a highly sensitive and specific biomarker of the disease that not only has diagnostic and prognostic value but also may predict the response to treatment.

References

• 1. Aggarwal R., Liao K., Nair R., Ringold S., Costenbader K.H.: Anti-citrullinatedpeptide antibody (ACPA) assays and their role inthe diagnosis of rheumatoid arthritis. Arthritis Rheum., 2009; 61:1472-1483
  Google Scholar
• 2. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., BinghamC.O. 3rd, Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D.,Combe B., Costenbader K.H., Dougados M., Emery P., Ferraccioli G.i wsp.: 2010 Rheumatoid arthritis classification criteria: an AmericanCollege of Rheumatology/European League Against Rheumatismcollaborative initiative. Arthritis Rheum., 2010; 62: 2569-2581
  Google Scholar
• 3. Ball E.M., Tan A.L., Fukuba E., McGonagle D., Grey A., SteinerG., Bell A.L., Rooney M.R.: A study of erosive phenotypes in lupusarthritis using magnetic resonance imaging and anti-citrullinatedprotein antibody, anti-RA33 and RF autoantibody status. Rheumatology,2014; 53: 1835-1843
  Google Scholar
• 4. Berglin E., Padyukov L., Sundin U., Hallmans G., Stenlund H., vanVenrooij W.J., Klareskog L., Dahlqvist S.R.: A combination of autoantibodiesto cyclic citrullinated peptide (CCP) and HLA-DRB1 locusantigens is strongly associated with future onset of rheumatoid arthritis.Arthritis Res. Ther., 2004; 6: R303-R308
  Google Scholar
• 5. Biernacka E., Ząbek J.: Przeciwciała dla cytrulinowanych białek –nowe kierunki badań. Reumatologia, 2010; 48: 262-270
  Google Scholar
• 6. Bukhari M., Lunt M., Harrison B.J., Scott D.G., Symmons, D.P.,Silman A.J.: Rheumatoid factor is the major predictor of increasingseverity of radiographic erosions in rheumatoid arthritis: resultsfrom the Norfolk Arthritis Register Study, a large inception cohort.Arthritis Rheum., 2002; 46: 906-912
  Google Scholar
• 7. De Rycke L., Peene I., Hoffman I.E., Kruithof E., Union A., MeheusL., Lebeer K., Wyns, B., Vincent C., Mielants H., Boullart L., Serre G.,Veys E.M., De Keyser F.: Rheumatoid factor and anticitrullinatedprotein antibodies in rheumatoid arthritis: diagnostic value, associationswith radiological progression rate, and extra-articularmanifestations. Ann. Rheum. Dis., 2004; 63: 1587-1593
  Google Scholar
• 8. Forslind K., Ahlmén M., Eberhardt K., Hafström I., Svensson B.,for the BARFOT Study Group: Prediction of radiological outcome inearly RA in clinical practice: role of antibodies to citrullinated peptides(anti-CCP). Ann. Rheum. Dis., 2004; 63: 1090-1095
  Google Scholar
• 10. Jearn L.H., Kim T.Y.: The influence of anti-cyclic citrullinatedpeptide on anticentromere antibody-positive rheumatoid arthritispatients. Arthritis Res. Ther., 2010; 12: 406
  Google Scholar
• 11. Jiang X., Trouw L.A., van Wesemael T.J., Shi J., Bengtsson C., KällbergH., Malmström V., Israelsson L., Hreggvidsdottir H., VerduijnW., Klareskog L., Alfredsson L., Huizinga T.W., Toes R.E., LundbergK., van der Woude D.: Anti-CarP antibodies in two large cohorts ofpatients with rheumatoid arthritis and their relationship to geneticrisk factors, cigarette smoking and other autoantibodies. Ann.Rheum. Dis., 2014; 73: 1761-1768
  Google Scholar
• 12. Kastbom A., Strandberg G., Lindroos A., Skogh T.: Anti-CCP antibodytest predicts the disease course during three years in early RA(the Swedish TIRA project). Ann. Rheum. Dis., 2004; 63: 1085-1089
  Google Scholar
• 13. Lashkari M., Noori A., Hajiimanouchehri F., Oveisi S., KazemifarA.M.: Determination of specificity and sensitivity of anti-RA 33 in diagnosis of early rheumatoid arthritis. Glob. J. Health Sci.,2014; 6: 292-297
  Google Scholar
• 14. Liao K.P., Kurreeman F., Li G., Duclos G., Murphy S., GuzmanR., Cai T., Gupta N., Gainer V., Schur P., Cui J., Denny J.C., SzolovitsP., Churchill S., Kohane I., Karlson E.W., Plenge R.M.: Associationsof autoantibodies, autoimmune risk alleles, and clinical diagnosesfrom the electronic medical records in rheumatoid arthritis casesand non-rheumatoid arthritis controls. Arthritis Rheum., 2013; 65:571-581
  Google Scholar
• 15. Maslyanskiy A., Lazareva N., Olinek P., Schierack P., Hentschel C.,Cuccato J., Bogdanos D.P., Lapin S.V., Roggenbuck D.: Anti-hnRNP B1(RA33) autoantibodies are associated with the clinical phenotype inRussian patients with rheumatoid arthritis and systemic sclerosis.J. Immunol. Res., 2014; 2014: 516593
  Google Scholar
• 16. Matsudaira R., Tamura N., Sekiya F., Ogasawara M., YamanakaK., Takasaki Y.: Anti-Ro/SSA antibodies are an independent factorassociated with an insufficient response to tumor necrosis factorinhibitors in patients with rheumatoid arthritis. J. Rheumatol.,2011; 38: 2346-2354
  Google Scholar
• 17. Nell-Duxneuner V., Machold K., Stamm T., Eberl G.,Heinzl H.,Hoefler E., Smolen J.S., Steiner G.: Autoantibody profiling in patientswith very early rheumatoid arthritis: a follow-up study. Ann. Rheum.Dis., 2010; 69: 169-174
  Google Scholar
• 18. Nielen M.M., van Schaardenburg D., Reesink H.W., van de StadtR.J., van der Horst-Bruinsma I.E., de Koning M.H., Habibuw M.R., VandenbrouckeJ.P., Dijkmans B.A.: Specific autoantibodies precede thesymptoms of rheumatoid arthritis: a study of serial measurementsin blood donors. Arthritis Rheum. 2004; 50: 380-386
  Google Scholar
• 19. Oreskes I., Siltzbach L.E.: Changes in rheumatoid factor activityduring the course of sarcoidosis. Am. J. Med., 1968; 44: 60-67
  Google Scholar
• 20. Puszczewicz M.: Badania serologiczne w chorobach reumatycznych.W: Wielka Interna, t. 9: Reumatologia, red.: M. Puszczewicz,Medical Tribune Polska, Warszawa 2010: 32-39
  Google Scholar
• 21. Puszczewicz M., Iwaszkiewicz C.: Role of anti-citrullinated proteinantibodies in diagnosis and prognosis of rheumatoid arthritis.Arch. Med. Sci., 2011; 7: 189-194
  Google Scholar
• 22. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H.,Hazes J.M., Breedveld F.C., van Venrooij W.J.: The diagnostic propertiesof rheumatoid arthritis antibodies recognizing a cyclic citrullinatedpeptide. Arthritis Rheum., 2000; 43: 155-163
  Google Scholar
• 23. Scott D.L., Wolfe F., Huizinga T.W.: Rheumatoid arthritis. Lancet,2010; 376: 1094-1108
  Google Scholar
• 24. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., HamannD., van Schaardenburg D., Toes R.E., Trouw L.A.: Anti-carbamylatedprotein (anti-CarP) antibodies precede the onset of rheumatoid arthritis.Ann. Rheum. Dis., 2014; 73: 780-783
  Google Scholar
• 25. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., Toes R.E.,Trouw L.A., van Schaardenburg D.: Anti-carbamylated protein antibodiesare present in arthralgia patients and predict the developmentof rheumatoid arthritis. Arthritis Rheum., 2013; 65: 911-915
  Google Scholar
• 26. Shmerling R.H.: Rheumatic disease: choosing the most usefuldiagnostic tests. Geriatrics, 1996; 51: 22-26
  Google Scholar
• 27. Stoop J.N., Liu B.S., Shi J., Jansen D.T. Hegen M., Huizinga T.W.,Trouw L.A., Toes R.E.: Antibodies specific for carbamylated proteinsprecede the onset of clinical symptoms in mice with collagen inducedarthritis. PLoS One, 2014; 9: e102163
  Google Scholar
• 28. Takase K., Horton S.C., Ganesha A., Das S., McHugh A., EmeryP., Savic S., Buch M.H.: What is the utility of routine ANA testing inpredicting development of biological DMARD-induced lupus andvasculitis in patients with rheumatoid arthritis? Data from a singlecentrecohort. Ann. Rheum. Dis., 2014; 73: 1695-1699
  Google Scholar
• 29. Tishler M., Golbrut B., Shoenfeld Y., Yaron M.: Anti-Ro(SSA) antibodiesin patients with rheumatoid arthritis – a possible marker forgold induced side effects. J. Rheumatol., 1994; 21: 1040-1042
  Google Scholar
• 30. Trouw L.A., Mahler M.: Closing the serological gap: promisingnovel biomarkers for the early diagnosis of rheumatoid arthritis.Autoimmun. Rev., 2012; 12: 318-322
  Google Scholar
• 31. Vallbracht I., Rieber J., Oppermann M., Förger F., Siebert U.,Helmke K.: Diagnostic and clinical value of anti-cyclic citrullinatedpeptide antibodies compared with rheumatoid factor isotypes inrheumatoid arthritis. Ann. Rheum. Dis., 2004; 63: 1079-1084
  Google Scholar
• 32. Van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J., de Jong B.A.,Breedveld F.C., Verweij C.L., Toes R.E., Huizinga T.W.J.: Autoantibodiesto cyclic citrullinated peptides predict progression to rheumatoidarthritis in patients with undifferentiated arthritis. A ProspectiveCohort Study. Arthritis Rheum., 2004; 50: 709-715
  Google Scholar
• 33. Van Venrooij W.J., Zendman A.J., Pruijn G.J.: Autoantibodies tocitrullinated antigens in (early) rheumatoid arthritis. Autoimmun.Rev., 2006; 6: 37-41
  Google Scholar
• 34. Vencovský J., Machácek S., Sedová L., Kafková J., Gatterová J.,Pesáková V., Růzicková S.: Autoantibodies can be prognostic markersof an erosive disease in early rheumatoid arthritis. Ann. Rheum.Dis., 2003; 62: 427-430
  Google Scholar
• 35. Willemze A., Toes R.E., Huizinga T.W., Trouw L.A.: New biomarkersin rheumatoid arthritis. Neth. J. Med., 2012; 70: 392-399
  Google Scholar
• 36. Williams V.L., Cohen P.R.: TNFα antagonist-induced lupus-likesyndrome: report and review of the literature with implicationsfor treatment with alternative TNFα antagonists. Int. J. Dermatol.,2011; 50: 619-625
  Google Scholar
• 37. Zanlorenzi L., Azevedo Pde O., Silva M.B., Skare T.: Anti-Ro antibodiesin rheumatoid arthritis. Acta Reumatol. Port., 2012; 37:149-152
  Google Scholar

Full text